Development of Mouse Tumors Resistant to Triethylene Melamine
Author Information
Author(s): ANNA MARIA WILLIAMS, ELAINE JORANGER
Primary Institution: University of Wisconsin Medical School
Hypothesis
Can mouse ascites tumors be developed to resist alkylating agents like triethylene melamine?
Conclusion
Mouse ascites tumors resistant to triethylene melamine were successfully developed and showed increased sensitivity to certain other drugs.
Supporting Evidence
- Sublines of Ehrlich carcinoma and Sarcoma 180 were developed to resist triethylene melamine.
- The resistant subline showed increased sensitivity to several antimetabolites.
- The resistance was stable for at least 8 transplant generations without the drug.
Takeaway
Scientists made mouse tumors that can survive a medicine called triethylene melamine, and these tumors can be treated better with other medicines.
Methodology
The study involved developing resistant sublines of mouse ascites tumors through consecutive passages in mice treated with triethylene melamine.
Limitations
The study does not address the mechanisms of resistance development, such as selection or mutation.
Participant Demographics
Female white Swiss mice, 20-25 g.
Want to read the original?
Access the complete publication on the publisher's website